PERIVASCULAR CA+ RECEPTOR--THERAPEUTIC SIGNIFICANCE

Information

  • Research Project
  • 2522636
  • ApplicationId
    2522636
  • Core Project Number
    R41HL059701
  • Full Project Number
    1R41HL059701-01
  • Serial Number
    59701
  • FOA Number
  • Sub Project Id
  • Project Start Date
    8/1/1998 - 26 years ago
  • Project End Date
    7/31/2000 - 24 years ago
  • Program Officer Name
  • Budget Start Date
    8/1/1998 - 26 years ago
  • Budget End Date
    7/31/2000 - 24 years ago
  • Fiscal Year
    1998
  • Support Year
    1
  • Suffix
  • Award Notice Date
    7/22/1998 - 26 years ago

PERIVASCULAR CA+ RECEPTOR--THERAPEUTIC SIGNIFICANCE

DESCRIPTION (Adapted from applicant's abstract): The long term goal of the proposal is to develop anti-hypertension drugs based on the premise that a distinct form of the parathyroid Ca2+ receptor (CaR) exists in perivascular nerves and that stimulation of this receptor leads to elaboration of a vasodilator substance. Preliminary data indicate that the CaR may be a sensory that is involved in the regulation of blood pressure. The applicant advances several lines of evidence to support his hypothesis that the CaR may be a key element in modulating vascular tone. In aim 1, a hypothesis will be tested which states that chronic or acute perivascular denervation results in reduction in perivascular CaR expression and a reduction in extracellular Ca2+ induced vascular tone. In such studies, denervation will be induced by two means and physiological methods, employed routinely by the applicant, will be used to study alterations in vascular tone. In aim 2, the interesting observation of an apparent change in splicing of the parathyroid calcium receptor in nerve will be investigated by 5'-RACE, cDNA cloning, and cDNA expression. PROPOSED COMMERCIAL APPLICATION: The goal and associated commercial application of this grant is to determine the feasibility of using the perivascular sensory nerve Ca2+ receptor as a target for the design of drugs that can be used as antihypertensive vasodilators with increased efficacy for salt sensitive hypertensive patients, including aged and minority populations.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R41
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG3
  • Study Section Name
  • Organization Name
    NPS PHARMACEUTICALS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    BEDMINSTER
  • Organization State
    NJ
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    07921
  • Organization District
    UNITED STATES